Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Recursion Pharmaceuticals (NASDAQ:RXRX) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 0 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 2 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.0, a high estimate of $11.00, and a low estimate of $6.00. Observing a downward trend, the current average is 18.18% lower than the prior average price target of $11.00.
Diving into Analyst Ratings: An In-Depth Exploration
The standing of Recursion Pharmaceuticals among...
Login or create a forever free account to read this news
Sign up/Log in
